Morgan Stanley bullish on these 2 pharma stocks which could give 32-47% return
Morgan Stanley also has overweight rating on Lupin with a target price at Rs 1,003, implying 47 percent potential upside from current levels as it believes the share price will rise in absolute terms over the next 30 days.